Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Achaogen, a biopharmaceutical company, has initiated its first Phase I clinical trial, which is designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of ACHN-490, the company's lead bactericidal agent, in at least 32 healthy volunteers.
Subscribe to our email newsletter
The trial – a randomized, double-blind, placebo-controlled, parallel group, dose-escalation study of intravenously administered ACHN-490 – is supported by the GBP4.1 million seeding drug discovery award received from the Wellcome Trust, as announced by the company in January 2009.
Kevin Judice, CEO of Achaogen, said: “We are very pleased that a promising neoglycoside compound discovered at Achaogen is being studied in our first clinical trial.
“We expect this initial clinical study of ACHN-490 to inform the dosing and trial design of our Phase II study in complicated urinary tract infection, as well as additional future studies addressing complicated intra-abdominal infections, bloodstream infections and other serious, unmet medical needs in the hospital setting. We expect to complete this trial in 2009, and initiate a Phase II study in early 2010.”